Introduction
• Aspergillus species are ubiquitous fungal saprophytes found in diverse ecological niches worldwide, A. fumigatus being the most prevalent (1).
• A. fumigatus is an opportunistic pathogen, a leading cause of invasive aspergillosis (IA) and usually causes infections in immunocompromised hosts resulting in high mortality rates.
• The triazole antifungal drugs ( itraconazole, posaconazole and voriconazole amongst others) are the first line drugs used in the treatment of IA however increasing evidence of azole resistant A. fumigatus is threatening their effectiveness.
• Triazole resistance can be acquired through two main routes-in the clinical setting trough the use of prolonged azole therapy or the agricultural route through the use of azole fungicides.
• The latter route is of greater concern; first described in the Netherlands, it is now reported globally and may be the leading mechanism of triazole resistance (2) .
• This emerging phenomenon of triazole resistance in A. fumigatus stresses the need for improved new diagnostic strategies i.e. early detection of resistance.
• Currently, anti-fungal susceptibility testing (AFST) is not carried out routinely on all clinically isolated A. fumigatus since this is both labour intensive and impractical therefore a screening method would be more favourable • VIPcheck™ plates provide a simple agar based screening method. Each 4-well plate contains a growth control (GC) well and 3 wells containing itraconazole, voriconazole and posaconazole. Post incubation, growth in any azole containing well is indicative of azole resistance prompting full AFST be carried out (3) . • Using a wet sterile swab, conidia were collected from a number of colonies (up to 5) of A. fumigatus to make a suspension of 0.5-2 McFarland. Each well was inoculated with 25ul of the suspension, incubated at 37•C in air for 48 hours and examined for growth. 
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Discussion
• A total of 18 strains of A. fumigatus were tested using the VIPcheck ™ plates.
• The 2 susceptible strains tested showed growth only in the growth control well. The other 16 strains tested (having previously been shown to be resistant to ≥1 of the triazole drugs by AFST and/or molecular methods in the Microbiology department, SJH) showed growth in one or more of the azole containing wells, thus prompting the medical scientist to carry out full AFST.
• VIPcheck™ plates are not intended to give an exact MIC; the preparation of the inoculum has a broad McFarland range of 0.5-2 and only one concentration of each azole drug is included in the plates. Rather, they are useful as a screening method to determine the need for further AFST and/or molecular testing and more importantly for earlier detection of triazole resistance in patients who will require treatment.
• Currently in the microbiology department in SJH, AFST is carried out using gradient MIC strips (Liofilchem™) and results interpreted using EUCAST guidelines.
• VIPcheck™ plates proved to be a reliable screening method for triazole resistance in A. fumigatus in SJH and moving forward, will be incorporated in our AFST algorithm for all A. fumigatus isolates given the significant cohort of immunocompromised patients in our hospital.
